Biotechnology research firm Creative Biolabs is making significant strides in COVID-19 research by developing advanced methodologies to identify potential antiviral treatments and inhibitors targeting the SARS-CoV-2 virus.
The company is focusing on multiple strategic approaches to drug discovery, with particular emphasis on understanding viral replication mechanisms. Central to their research is studying the main protease of SARS-CoV-2, a critical enzyme in viral gene expression and replication. By developing precise protease detection services, researchers can evaluate potential drug candidates more effectively.
Creative Biolabs has developed a comprehensive suite of research services designed to accelerate COVID-19 therapeutic development. These include sophisticated screening techniques such as spike-pseudovirus neutralization tests, thermal shift binding assays, and cytopathic effect detection methods.
A key innovation in their research involves antiviral peptide discovery. By utilizing peptide microarray analysis, the company screens potential peptides that could block virus attachment or inhibit viral multiplication. Specific areas of focus include fusion peptides and ACE2-based peptides, which represent promising alternative treatment pathways.
The company's approach leverages advanced technological platforms and specialized cell lines, including TMPRSS2-enhanced and ACE2 co-enhanced cell lines. These sophisticated research tools enable more precise evaluation of viral replication and potential inhibitor effectiveness.
By combining high-accuracy cytopathic effect detection, advanced microscopic imaging, and modern cell counting methods, Creative Biolabs aims to provide researchers with reliable data to support global efforts in combating the COVID-19 pandemic.
